SlideShare a Scribd company logo
1 of 40
Download to read offline
Molecular mechanism underlying Depression: The
relationship between serotonin system and glutamate
system in mouse cortical neurons and HT22 cells
Adiba SHABNAM
2015
Overview
•Depression: Definition
•Causes
•Affected Brain areas
•Antidepressant: Mechanism
•Serotonin Theory
•Glutamate and GABA Theory
•Objective
•Experimental Method
•Results
•Conclusion
DEPRESSION
A common psychiatric
disorder characterized
by low mood, loss of
pleasure, sleep and
appetite changes, poor
concentration and
suicidal tendency
Depression
Why to study depression?
• Most common psychiatric
disorder
• All age group affected (max.
40-59 yrs)
• Women are more at risk
• Lifetime prevalence 16.2 %
(USA)
• Only 20 % people experience
the symptoms of depression.
• Maximum global burden of
disease in 2030 (WHO, 2008)
Causes of depression
• Genetic or hereditary
• Biochemical - monoamine
• Endocrine factors
• psychological factors
Involved Brain Parts
Involvement of Cortex in depression
Abnormal metabolism in the prefrontal cortex in various mood disorders
Involvement of Hippocampus in depression
Reduced Hippocampal volume (Bremner et al, 2000,Lange et al, 2004; Macmaster et al, 2007;Brien et
al 2004, Sheline et al 1995 )
Chronic stress selectively reduces
hippocampal volume in rats: a
longitudinal MRI study (Lee, 2009)
Antidepressant SEROTONIN
Serotonin
TheoryofDepression
SSRI blocks
5-HT reuptake
Serotonin theory
• Most widely accepted hypothesis
• Depletion of 5-HT in depressed patients
• Antidepressants like SSRI inhibits its re-uptake and
increases its concentration in the synaptic cleft.
LIMITATIONS
• Not all depressed patients (50%) responds to 5-HT
agonists and SSRI. (Mahar et al, 2014)
• Delayed onset of effect (2 weeks)
• A reduction in 5-HT level does not precipitate in
depressive phenotype in healthy individuals
What is the reason for the lag?
Glutamate
TheoryofDepression
• Increased plasma glutamate level in
depression (Altamura et al)
• Ketamine and mGlu2/3 R antagonist -
antidepressant
• 5-HT1A R stimulation by ketamine &
mGlu2/3 R antagonist (Fukumoto et al,
2014)
Glutamate Receptor: classification
Glutamatergic theory
Mechanism of action of
Ketamine
AMPA-R activation
mTOR signalling pathway
activated in prefrontal cortex
GluR1, Synapsin, spine density
Synaptogenesis
BDNF translation
Kavalali, 2012
Glutamate system also has antidepressant
effect
Group&I&and&II&mGluR&antagonists&
NMDAR&antagonists&
An6depressant
5HT1A&agonist&
5HT2A/2C&antagonist&
Ac6va6on&of&AMPAR
BDNF&	
&
mTOR&signaling&	
&
Synapse&forma6on	
5HT&&&&	
&
BDNF&	
 (hippo,&cortex)&
GABA
TheoryofDepression
• Overlapping anxiety and depression circuit (kalueff, 2007)
• GABA implicated in SSRI action (Mohler, 2012)
• Alteration of GABA-A R in depression (Fatemi, 2013)
5HT1A & 5HT2A/2C receptors in depression
5HT1A R
•5HT-1a R agonists (8-OH-DPAT) produce antidepressant like
effect (Cryan, 2005).
•5HT-1A auto-receptor desensitize with antidepressant drugs.
•Presynaptic 5HT1A R (autoreceptor): risk for depression
•Postsynaptic 5HT1A R : produce antidepressant effect
•5HT-1A R mediates ketamine effect (Fukumoto et al, 2014)
5HT2A R
• Antidepressant drugs block 5-HTA R mediated responses
(Celada et al, 2004)
• Treatment with 5-HT2A/2C R agonist DOI caused increase
release of glutamate in the cortex blocked by pretreatment
with 5HT2A R antagonist (Scruggs, 2003)
Objective of the experiment
Investigation of the effect
of 5-HT1A agonist and 5-
HT 2A/2C agonist on m-
RNA expression of
AMPA-R (GluR1, GluR2,
GluR3,GluR4), GABA-
Aα1 and BDNF
5HT 2A/2C agonist
5HT,BDNF
Group II mGluR
antagonist
NMDA-R antagonist
AMPA-R activation
mTOR signaling BDNF,
Synaptogenesis
Antidepression
GABA-A R
5HT1A agonist
Mechanism of Depression
Experiment
m-RNA expression of GluR1, GluR2,
GluR3, GluR4, BDNF, GABA-A R
5-HT 1A agonist
(8-OH-DPAT)
5-HT 2A/2C agonist
(DOI)
Experimental methodology
HT-22 cells culture
5-HT 1A & 5-HT 2A/2C agonists addition
Total RNA Isolation
Real time PCR Analysis
Cell culture and Trypsinization
HT-22 cells +S-DMEM
HBSS + 0.05% trypsin-EDTA
Drug Addition: Serotonin Agonist
8-OH-DPAT and DOI at 4 different concentrations
8-OH DPAT
(0 nM)
8-OH DPAT
(1nM)
8-OH DPAT
(10nM)
8-OH DPAT
(100nM)
DOI
(0 nM)
DOI
(1 nM)
DOI
(10 nM)
DOI
(100 nM)
After 4 hours
RNA Isolation
Sample
+
RNAiso Plus
+
Chloroform
+
Isopropanol
+
RNase free water
Absorption Spectrometry
Total RNA
concentration
measurement
DNA Removal
Thermal cycler
Isolated RNA
+
RNase free water
+
7 * gDNA wipeout buffer
Reverse Transcription
Template RNA
+
RT Primer mix
+
Quantiscript Reverse Transcriptase
+
Quantiscript RT Buffer
+
Placed in thermal cycler
REAL TIME PCR
Amplification Plot
Dissociation Curve
Melting curve
Amplification Curve
Amplification Plots
Fluorescence(PrimaryCurve)
-10
1.429
12.857
24.286
35.714
47.143
58.571
70
Cycles
0 10 20 30 40 50
FAM A2 FAM A3 FAM A4
FAM A5 FAM A6 FAM A7
FAM A8 FAM A9 FAM A10
FAM B2 FAM B3 FAM B4
FAM B5 FAM B6 FAM B7
FAM B8 FAM B9 FAM B10
FAM C2 FAM C3 FAM C4
FAM C5 FAM C6 FAM C7
FAM C8 FAM C9 FAM C10
FAM D2 FAM D3 FAM D4
FAM D5 FAM D6 FAM D7
FAM D8 FAM D9 FAM D10
FAM E2 FAM E3 FAM E4
FAM E5 FAM E6 FAM E7
FAM E8 FAM E9 FAM E10
FAM F4 FAM F7 FAM F10
FAM G4 FAM G7 FAM G10
FAM H4 FAM H7 FAM H10
Dissociation Curve
Dissociation Curve
Fluorescence(1stDerivative)
-500
500
1500
2500
3500
Temperature
60 67.2 74.4 81.6 88.8 96
FAM A2 FAM A3
FAM A4 FAM A5
FAM A6 FAM A7
FAM A8 FAM A9
FAM A10 FAM B2
FAM B3 FAM B4
FAM B5 FAM B6
FAM B7 FAM B8
FAM B9 FAM B10
FAM C2 FAM C3
FAM C4 FAM C5
FAM C6 FAM C7
FAM C8 FAM C9
FAM C10 FAM D2
FAM D3 FAM D4
FAM D5 FAM D6
FAM D7 FAM D8
FAM D9 FAM D10
FAM E2 FAM E3
FAM E4 FAM E5
FAM E6 FAM E7
FAM E8 FAM E9
FAM E10 FAM F4
FAM F7 FAM F10
FAM G4 FAM G7
FAM G10 FAM H4
FAM H7 FAM H10
RESULTS
Relative expression: 8-OH-DPAT on cortical cells
GluR2
RelativeExplession
0.0
15.0
30.0
45.0
60.0
8OH_0nM 8OH_1nM 8OH_10nM 8OH_100nM
GluR1
RelativeExpression
0.0
0.4
0.8
1.2
1.6
8OH_0nM 8OH_1nM 8OH_10nM 8OH_100nM
Decreased m-RNA expression of GluR1
&
Increased m-RNA expression of GluR2
Relative expression: 8-OH-DPAT on HT-22 cells
GluR3
RelativeExpression
0.00E+00
2.50E-03
5.00E-03
7.50E-03
1.00E-02
8OH 0nM 8OH 1nM 8OH 10nM 8OH 100nM
BDNF
RelativeExpression
0.00E+00
1.25E-02
2.50E-02
3.75E-02
5.00E-02
8OH 0nM 8OH 1nM 8OH 10nM 8OH 100nM
Decreased m-RNA expression of GluR3 & BDNF
RelativeExpression
0.00E+00
2.50E+00
5.00E+00
7.50E+00
1.00E+01
DOI 0nM DOI 1nM DOI 10nM DOI 100nM
Relative expression: DOI on HT-22 cells
Increased mRNA expression of BDNF
Conclusion • Decreased mRNA expression
of GluR1 and increased
mRNA expression of GluR2
by 8-OH-DPAT
• Decreased mRNA expression
of GluR3 and BDNF by 8-OH-
DPAT
• Increased mRNA expression
of GluR3 and BDNF by DOI
• No amplification of GluR1,
GluR2, GluR4, GABA-Aα1.
SHORTFALLS
• Manual error ?
• defective primers ? (>1 year)
• cDNA of HT-22 cells got
modified.Interaction between
GluR and cDNA of HT22 cells
depression

More Related Content

What's hot

What's hot (20)

Serotonin
Serotonin Serotonin
Serotonin
 
Glutamate & schizophrenia
Glutamate & schizophreniaGlutamate & schizophrenia
Glutamate & schizophrenia
 
Glutamate 33
Glutamate 33Glutamate 33
Glutamate 33
 
Serotonergic system ravi
Serotonergic system raviSerotonergic system ravi
Serotonergic system ravi
 
SEROTONIN (5-HT) NEUROTRANSMITTER
SEROTONIN (5-HT) NEUROTRANSMITTER �SEROTONIN (5-HT) NEUROTRANSMITTER �
SEROTONIN (5-HT) NEUROTRANSMITTER
 
Hippocampus and serotonin
Hippocampus and serotoninHippocampus and serotonin
Hippocampus and serotonin
 
Serotonin, 5-hydroxytryptamine (5-HT)
Serotonin, 5-hydroxytryptamine (5-HT)Serotonin, 5-hydroxytryptamine (5-HT)
Serotonin, 5-hydroxytryptamine (5-HT)
 
Serotonin; receptors, function and chemistry
Serotonin; receptors, function and chemistrySerotonin; receptors, function and chemistry
Serotonin; receptors, function and chemistry
 
Glutamate and schizophrenia
Glutamate and schizophreniaGlutamate and schizophrenia
Glutamate and schizophrenia
 
Neurotransmitters- serotonin & dopamine by dr. rujul modi
Neurotransmitters- serotonin & dopamine by dr. rujul modiNeurotransmitters- serotonin & dopamine by dr. rujul modi
Neurotransmitters- serotonin & dopamine by dr. rujul modi
 
Serotonin
SerotoninSerotonin
Serotonin
 
Serotonin Syndrome
Serotonin SyndromeSerotonin Syndrome
Serotonin Syndrome
 
Serotonin
SerotoninSerotonin
Serotonin
 
Serotonin or 5 hydroxy-tryptamine and its antagonists-Dr.Jibachha Sah,M.V.Sc,...
Serotonin or 5 hydroxy-tryptamine and its antagonists-Dr.Jibachha Sah,M.V.Sc,...Serotonin or 5 hydroxy-tryptamine and its antagonists-Dr.Jibachha Sah,M.V.Sc,...
Serotonin or 5 hydroxy-tryptamine and its antagonists-Dr.Jibachha Sah,M.V.Sc,...
 
Antipsychotics
AntipsychoticsAntipsychotics
Antipsychotics
 
Serotonin
SerotoninSerotonin
Serotonin
 
Serotonin & drugs acing on serotonin receptors
Serotonin & drugs acing on serotonin receptorsSerotonin & drugs acing on serotonin receptors
Serotonin & drugs acing on serotonin receptors
 
SEROTONIN (VK)
SEROTONIN (VK)SEROTONIN (VK)
SEROTONIN (VK)
 
Serotonin.dr.asa
Serotonin.dr.asaSerotonin.dr.asa
Serotonin.dr.asa
 
5 ht
5 ht5 ht
5 ht
 

Similar to depression

精神分裂症5-羟色胺病理生理机制
精神分裂症5-羟色胺病理生理机制精神分裂症5-羟色胺病理生理机制
精神分裂症5-羟色胺病理生理机制BingoMed
 
Investigations of TARP gamma-8 Null Mice
Investigations of TARP gamma-8 Null MiceInvestigations of TARP gamma-8 Null Mice
Investigations of TARP gamma-8 Null MicePatrick Stutz
 
Bromocriptine for Special Population - Adult ADHD
Bromocriptine for Special Population - Adult ADHDBromocriptine for Special Population - Adult ADHD
Bromocriptine for Special Population - Adult ADHDOlayinka Awofodu
 
Hanipsych, serotonine and depression
Hanipsych, serotonine and depressionHanipsych, serotonine and depression
Hanipsych, serotonine and depressionHani Hamed
 
Schizophrenia and Psychosis: Antipsychotics
Schizophrenia and Psychosis: AntipsychoticsSchizophrenia and Psychosis: Antipsychotics
Schizophrenia and Psychosis: AntipsychoticsPranav Sopory
 
Blain_AlzResTherapy_2016_Characterization of FRM-36143 as a new γ-secretase m...
Blain_AlzResTherapy_2016_Characterization of FRM-36143 as a new γ-secretase m...Blain_AlzResTherapy_2016_Characterization of FRM-36143 as a new γ-secretase m...
Blain_AlzResTherapy_2016_Characterization of FRM-36143 as a new γ-secretase m...Gerhard Koenig
 
Brain Chemistry And The Medical Treatment Of Major Depression
Brain Chemistry And The Medical Treatment Of Major DepressionBrain Chemistry And The Medical Treatment Of Major Depression
Brain Chemistry And The Medical Treatment Of Major DepressionGiakas
 
Neurotossicità iperammoniemia martinelli
Neurotossicità iperammoniemia martinelliNeurotossicità iperammoniemia martinelli
Neurotossicità iperammoniemia martinelliCentroMalattieRareFVG
 
Steroids in epilepsies
Steroids in epilepsiesSteroids in epilepsies
Steroids in epilepsiesMahendra Putra
 
Advancement in anti-depression drugs
Advancement in anti-depression drugsAdvancement in anti-depression drugs
Advancement in anti-depression drugsDiwyanshi Zinzuvadia
 
biology, basic
biology, basic biology, basic
biology, basic Hani Hamed
 

Similar to depression (20)

精神分裂症5-羟色胺病理生理机制
精神分裂症5-羟色胺病理生理机制精神分裂症5-羟色胺病理生理机制
精神分裂症5-羟色胺病理生理机制
 
serotonin.pptx
serotonin.pptxserotonin.pptx
serotonin.pptx
 
Investigations of TARP gamma-8 Null Mice
Investigations of TARP gamma-8 Null MiceInvestigations of TARP gamma-8 Null Mice
Investigations of TARP gamma-8 Null Mice
 
Bromocriptine for Special Population - Adult ADHD
Bromocriptine for Special Population - Adult ADHDBromocriptine for Special Population - Adult ADHD
Bromocriptine for Special Population - Adult ADHD
 
Hanipsych, serotonine and depression
Hanipsych, serotonine and depressionHanipsych, serotonine and depression
Hanipsych, serotonine and depression
 
Schizophrenia and Psychosis: Antipsychotics
Schizophrenia and Psychosis: AntipsychoticsSchizophrenia and Psychosis: Antipsychotics
Schizophrenia and Psychosis: Antipsychotics
 
Blain_AlzResTherapy_2016_Characterization of FRM-36143 as a new γ-secretase m...
Blain_AlzResTherapy_2016_Characterization of FRM-36143 as a new γ-secretase m...Blain_AlzResTherapy_2016_Characterization of FRM-36143 as a new γ-secretase m...
Blain_AlzResTherapy_2016_Characterization of FRM-36143 as a new γ-secretase m...
 
Brain Chemistry And The Medical Treatment Of Major Depression
Brain Chemistry And The Medical Treatment Of Major DepressionBrain Chemistry And The Medical Treatment Of Major Depression
Brain Chemistry And The Medical Treatment Of Major Depression
 
Jordi Mestres
Jordi MestresJordi Mestres
Jordi Mestres
 
Armstead, William
Armstead, WilliamArmstead, William
Armstead, William
 
Antiparkinson drugs
Antiparkinson drugsAntiparkinson drugs
Antiparkinson drugs
 
Neurotossicità iperammoniemia martinelli
Neurotossicità iperammoniemia martinelliNeurotossicità iperammoniemia martinelli
Neurotossicità iperammoniemia martinelli
 
Steroids in epilepsies
Steroids in epilepsiesSteroids in epilepsies
Steroids in epilepsies
 
Ads treatment
Ads treatmentAds treatment
Ads treatment
 
A novel PPAR pan-agonist, 2-(4-(5,6-methylenedioxybenzo[d]thiazol-2-yl)-2-met...
A novel PPAR pan-agonist, 2-(4-(5,6-methylenedioxybenzo[d]thiazol-2-yl)-2-met...A novel PPAR pan-agonist, 2-(4-(5,6-methylenedioxybenzo[d]thiazol-2-yl)-2-met...
A novel PPAR pan-agonist, 2-(4-(5,6-methylenedioxybenzo[d]thiazol-2-yl)-2-met...
 
Advancement in anti-depression drugs
Advancement in anti-depression drugsAdvancement in anti-depression drugs
Advancement in anti-depression drugs
 
Class intro to cns
Class intro to cnsClass intro to cns
Class intro to cns
 
biology, basic
biology, basic biology, basic
biology, basic
 
M.Sc Presentation
M.Sc PresentationM.Sc Presentation
M.Sc Presentation
 
Serotonina e Receptores
Serotonina e ReceptoresSerotonina e Receptores
Serotonina e Receptores
 

depression

  • 1. Molecular mechanism underlying Depression: The relationship between serotonin system and glutamate system in mouse cortical neurons and HT22 cells Adiba SHABNAM 2015
  • 2. Overview •Depression: Definition •Causes •Affected Brain areas •Antidepressant: Mechanism •Serotonin Theory •Glutamate and GABA Theory •Objective •Experimental Method •Results •Conclusion
  • 3.
  • 4. DEPRESSION A common psychiatric disorder characterized by low mood, loss of pleasure, sleep and appetite changes, poor concentration and suicidal tendency Depression
  • 5. Why to study depression? • Most common psychiatric disorder • All age group affected (max. 40-59 yrs) • Women are more at risk • Lifetime prevalence 16.2 % (USA) • Only 20 % people experience the symptoms of depression. • Maximum global burden of disease in 2030 (WHO, 2008)
  • 6. Causes of depression • Genetic or hereditary • Biochemical - monoamine • Endocrine factors • psychological factors
  • 8. Involvement of Cortex in depression Abnormal metabolism in the prefrontal cortex in various mood disorders
  • 9. Involvement of Hippocampus in depression Reduced Hippocampal volume (Bremner et al, 2000,Lange et al, 2004; Macmaster et al, 2007;Brien et al 2004, Sheline et al 1995 ) Chronic stress selectively reduces hippocampal volume in rats: a longitudinal MRI study (Lee, 2009)
  • 12. Serotonin theory • Most widely accepted hypothesis • Depletion of 5-HT in depressed patients • Antidepressants like SSRI inhibits its re-uptake and increases its concentration in the synaptic cleft. LIMITATIONS • Not all depressed patients (50%) responds to 5-HT agonists and SSRI. (Mahar et al, 2014) • Delayed onset of effect (2 weeks) • A reduction in 5-HT level does not precipitate in depressive phenotype in healthy individuals
  • 13. What is the reason for the lag?
  • 14. Glutamate TheoryofDepression • Increased plasma glutamate level in depression (Altamura et al) • Ketamine and mGlu2/3 R antagonist - antidepressant • 5-HT1A R stimulation by ketamine & mGlu2/3 R antagonist (Fukumoto et al, 2014)
  • 15.
  • 17. Glutamatergic theory Mechanism of action of Ketamine AMPA-R activation mTOR signalling pathway activated in prefrontal cortex GluR1, Synapsin, spine density Synaptogenesis BDNF translation Kavalali, 2012
  • 18. Glutamate system also has antidepressant effect Group&I&and&II&mGluR&antagonists& NMDAR&antagonists& An6depressant 5HT1A&agonist& 5HT2A/2C&antagonist& Ac6va6on&of&AMPAR BDNF& & mTOR&signaling& & Synapse&forma6on 5HT&&&& & BDNF& (hippo,&cortex)&
  • 19. GABA TheoryofDepression • Overlapping anxiety and depression circuit (kalueff, 2007) • GABA implicated in SSRI action (Mohler, 2012) • Alteration of GABA-A R in depression (Fatemi, 2013)
  • 20. 5HT1A & 5HT2A/2C receptors in depression 5HT1A R •5HT-1a R agonists (8-OH-DPAT) produce antidepressant like effect (Cryan, 2005). •5HT-1A auto-receptor desensitize with antidepressant drugs. •Presynaptic 5HT1A R (autoreceptor): risk for depression •Postsynaptic 5HT1A R : produce antidepressant effect •5HT-1A R mediates ketamine effect (Fukumoto et al, 2014) 5HT2A R • Antidepressant drugs block 5-HTA R mediated responses (Celada et al, 2004) • Treatment with 5-HT2A/2C R agonist DOI caused increase release of glutamate in the cortex blocked by pretreatment with 5HT2A R antagonist (Scruggs, 2003)
  • 21. Objective of the experiment Investigation of the effect of 5-HT1A agonist and 5- HT 2A/2C agonist on m- RNA expression of AMPA-R (GluR1, GluR2, GluR3,GluR4), GABA- Aα1 and BDNF
  • 22. 5HT 2A/2C agonist 5HT,BDNF Group II mGluR antagonist NMDA-R antagonist AMPA-R activation mTOR signaling BDNF, Synaptogenesis Antidepression GABA-A R 5HT1A agonist Mechanism of Depression
  • 23. Experiment m-RNA expression of GluR1, GluR2, GluR3, GluR4, BDNF, GABA-A R 5-HT 1A agonist (8-OH-DPAT) 5-HT 2A/2C agonist (DOI)
  • 24. Experimental methodology HT-22 cells culture 5-HT 1A & 5-HT 2A/2C agonists addition Total RNA Isolation Real time PCR Analysis
  • 25. Cell culture and Trypsinization HT-22 cells +S-DMEM HBSS + 0.05% trypsin-EDTA
  • 26. Drug Addition: Serotonin Agonist 8-OH-DPAT and DOI at 4 different concentrations 8-OH DPAT (0 nM) 8-OH DPAT (1nM) 8-OH DPAT (10nM) 8-OH DPAT (100nM) DOI (0 nM) DOI (1 nM) DOI (10 nM) DOI (100 nM) After 4 hours
  • 29. DNA Removal Thermal cycler Isolated RNA + RNase free water + 7 * gDNA wipeout buffer
  • 30. Reverse Transcription Template RNA + RT Primer mix + Quantiscript Reverse Transcriptase + Quantiscript RT Buffer + Placed in thermal cycler
  • 33. Amplification Curve Amplification Plots Fluorescence(PrimaryCurve) -10 1.429 12.857 24.286 35.714 47.143 58.571 70 Cycles 0 10 20 30 40 50 FAM A2 FAM A3 FAM A4 FAM A5 FAM A6 FAM A7 FAM A8 FAM A9 FAM A10 FAM B2 FAM B3 FAM B4 FAM B5 FAM B6 FAM B7 FAM B8 FAM B9 FAM B10 FAM C2 FAM C3 FAM C4 FAM C5 FAM C6 FAM C7 FAM C8 FAM C9 FAM C10 FAM D2 FAM D3 FAM D4 FAM D5 FAM D6 FAM D7 FAM D8 FAM D9 FAM D10 FAM E2 FAM E3 FAM E4 FAM E5 FAM E6 FAM E7 FAM E8 FAM E9 FAM E10 FAM F4 FAM F7 FAM F10 FAM G4 FAM G7 FAM G10 FAM H4 FAM H7 FAM H10
  • 34. Dissociation Curve Dissociation Curve Fluorescence(1stDerivative) -500 500 1500 2500 3500 Temperature 60 67.2 74.4 81.6 88.8 96 FAM A2 FAM A3 FAM A4 FAM A5 FAM A6 FAM A7 FAM A8 FAM A9 FAM A10 FAM B2 FAM B3 FAM B4 FAM B5 FAM B6 FAM B7 FAM B8 FAM B9 FAM B10 FAM C2 FAM C3 FAM C4 FAM C5 FAM C6 FAM C7 FAM C8 FAM C9 FAM C10 FAM D2 FAM D3 FAM D4 FAM D5 FAM D6 FAM D7 FAM D8 FAM D9 FAM D10 FAM E2 FAM E3 FAM E4 FAM E5 FAM E6 FAM E7 FAM E8 FAM E9 FAM E10 FAM F4 FAM F7 FAM F10 FAM G4 FAM G7 FAM G10 FAM H4 FAM H7 FAM H10
  • 36. Relative expression: 8-OH-DPAT on cortical cells GluR2 RelativeExplession 0.0 15.0 30.0 45.0 60.0 8OH_0nM 8OH_1nM 8OH_10nM 8OH_100nM GluR1 RelativeExpression 0.0 0.4 0.8 1.2 1.6 8OH_0nM 8OH_1nM 8OH_10nM 8OH_100nM Decreased m-RNA expression of GluR1 & Increased m-RNA expression of GluR2
  • 37. Relative expression: 8-OH-DPAT on HT-22 cells GluR3 RelativeExpression 0.00E+00 2.50E-03 5.00E-03 7.50E-03 1.00E-02 8OH 0nM 8OH 1nM 8OH 10nM 8OH 100nM BDNF RelativeExpression 0.00E+00 1.25E-02 2.50E-02 3.75E-02 5.00E-02 8OH 0nM 8OH 1nM 8OH 10nM 8OH 100nM Decreased m-RNA expression of GluR3 & BDNF
  • 38. RelativeExpression 0.00E+00 2.50E+00 5.00E+00 7.50E+00 1.00E+01 DOI 0nM DOI 1nM DOI 10nM DOI 100nM Relative expression: DOI on HT-22 cells Increased mRNA expression of BDNF
  • 39. Conclusion • Decreased mRNA expression of GluR1 and increased mRNA expression of GluR2 by 8-OH-DPAT • Decreased mRNA expression of GluR3 and BDNF by 8-OH- DPAT • Increased mRNA expression of GluR3 and BDNF by DOI • No amplification of GluR1, GluR2, GluR4, GABA-Aα1. SHORTFALLS • Manual error ? • defective primers ? (>1 year) • cDNA of HT-22 cells got modified.Interaction between GluR and cDNA of HT22 cells